-
Abstract Number: OC 75.1
A 3D microvasculature assay reveals novel sub-cellular dynamics of megakaryocyte endothelial barrier interactions, proplatelet formation and release.
-
Abstract Number: PO0048
A Cardiac Amyloidosis Presentation: Atrial Mass Versus Thrombus
-
Abstract Number: PB0665
A Case of Discrepant One-stage and Chromogenic Factor VIII Activity Assay in a Patient with a Hemizygous Arg550His Mutation in the F8 Gene
-
Abstract Number: PB0708
A Case of Factor VII Deficiency Presented With Repeated Rectal Bleeding
-
Abstract Number: VPB0841
A case of hematidrosis complicated with von Willebrand disease
-
Abstract Number: VPB1249
A case report of Inherited platelet function disorders caused by double site mutation of RASGRP2 gene and pedigree analysis
-
Abstract Number: OC 52.4
A case series examining the safety and efficacy of anticoagulation management in pregnant women with metallic heart valves
-
Abstract Number: VPB1381
A Case Series In Pregnant Women Receiving Therapeutic LMWH, Is Monitoring Anti-Xa Levels Necessary?
-
Abstract Number: OC 17.3
A collaborative study to harmonize thrombin generation assays for measurement of procoagulant activity in immune globulins
-
Abstract Number: PB1086
A comparative in vitro study of the coagulation effects of branded versus generic preparations of rivaroxaban
-
Abstract Number: VPB0636
A Comparative Study Of Intravenous Bolus Versus Bolus With Continuous Infusion Of Tranexamic Acid To Reduce Blood Loss In Major Surgical Procedures
-
Abstract Number: VPB0607
A Comparison of eNOS-based Platelet Subpopulation Ratios and Platelet VEGF Content within COVID-19
-
Abstract Number: PB0479
A comparison of thrombin generation ex vivo circuit and in critically ill patients requiring Extracorporeal Membrane Oxygenation
-
Abstract Number: PB0484
A comparison study of ROTEM® Sigma and ROTEM® Delta in a major tertiary hospital
-
Abstract Number: OC 56.1
A Cross-Ancestry Meta-Analysis of Venous Thromboembolism Genetic Associations
-
Abstract Number: OC 26.2
A dose-escalation phase 1 clinical trial of autologous iPSC-derived platelets (iPLAT1)
-
Abstract Number: PB1239
A Familial Case of MYH9 Gene Mutation Associated with Impaired Platelet Functionality and Structural Alterations
-
Abstract Number: PO0012
A frequency of anti-PF4/heparin antibodies and LA in patients with COVID-19
-
Abstract Number: OC 37.4
A humanized mouse model to assess the therapeutic potential of IdeS in hemophilia A with inhibitors
-
Abstract Number: PB1113
A method for measuring chromogenic factor VIII activity unbiased by the presence of the bispecific antibody Emicizumab
-
Abstract Number: OC 49.3
A microfluidic model to study the initiation of venous thrombosis
-
Abstract Number: PB0051
A Multicenter Cohort Study of COVID-19 Associated Venous Thromboembolism in Admitted Patients Followed Longitudinally 3-Months After Discharge
-
Abstract Number: OC 13.5
A Multicenter Randomized Clinical Trial of Modulation of Host Thromboinflammatory Response in Hospitalized Patients with COVID-19: The DAWn-Antico study
-
Abstract Number: VPB0141
A near real-time surveillance algorithm to identify in-hospital VITT cases
-
Abstract Number: PB0666
A new FVIII chromogenic assay with bovine FX is sensitive enough for the diagnosis of severe haemophilia A.
-
Abstract Number: OC 44.3
A new mouse model of impaired fibrin α-chain crosslinking shows increased venous thrombembolism
-
Abstract Number: PB0804
A new type 1 von Willebrand Disease (VWD) characterized by increased clearance of von Willebrand Factor (VWF) due to the heterozygous p.P1127S mutation: clinical phenotype and pathogenic mechanisms.
-
Abstract Number: OC 41.5
A novel and unique mechanism of αIIbβ3 regulation in platelets
-
Abstract Number: PB0295
A Novel Assay to Investigate Thrombogenesis in TTP Patients
-
Abstract Number: PB1186
A novel chemiluminescent-based Thrombin Generation Assay for near-patient monitoring.
-
Abstract Number: PB0711
A novel homozygous KLKB1 missense variant causative of severe Prekallikrein deficiency.
-
Abstract Number: PB1001
A Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Hemostatic and Anti-Inflammatory Activities
-
Abstract Number: VPB1116
A novel material for the improvement of HIT detection
-
Abstract Number: OC 10.3
A novel model of RUNX1-haploinsufficient (RUNX1Lo): Human megakaryocytes infused into mice further characterizes this defect and identifies potential therapeutics
-
Abstract Number: PB1111
A novel prothrombin R533Q variant in patient with recurrent venous thrombosis
-
Abstract Number: PB0334
A novel R1162S variant in MYH9 alters the biochemical interactions and dynamics of NMMHC-IIA, induces severe macrothrombocytopenia and perturbs leukocyte function and cellular coherence
-
Abstract Number: PB0810
A novel role for subtle enhanced VWF clearance in Low VWF pathogenesis highlights limitations of VWFpp/VWF:Ag ratio assessment of clearance.
-
Abstract Number: PB1057
A novel, easy-to-use ADAMTS13 activity assay using a fiber-optic surface plasmon resonance biosensor for diagnosis of thrombotic thrombocytopenic purpura
-
Abstract Number: OC 65.3
A Phase 2 Trial Evaluating the Safety and Antithrombotic Efficacy of AB002, a First-in-class Protein C Activator in End-stage Renal Disease Patients on Heparin-free Hemodialysis
-
Abstract Number: LB 01.1
A Phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis
-
Abstract Number: PB0045
A pilot, open-label, phase II clinical trial of nebulised recombinant tissue-plasminogen activator in patients with COVID-19 acute respiratory distress syndrome: the PACA trial
-
Abstract Number: PB0030
A Population Cohort Study to Evaluate the Risk of Ischemic Stroke Among Individuals with a New Diagnosis of Cancer Compared to Matched Cancer-Free Controls: Impact of Prior Stroke History
-
Abstract Number: OC 47.4
A Post Hoc Analysis of Individuals With Severe Hemophilia A and Inhibitors From the PUPs A-LONG Study
-
Abstract Number: PB0673
A Post-authorization Safety Surveillance Study To Report Clinical Experience With Purified FIX Concentrate in Pediatric Patients With Hemophilia B
-
Abstract Number: PB1091
A potential suitable alternative to Triton-X-100 for use in sample preparation for platelet nucleotide analysis
-
Abstract Number: PB0155
A potential use of leukocyte-platelet rich fibrin secretome to improve wound healing and bone regeneration
-
Abstract Number: PB0552
A Probable Therapeutic for a Child with Inherited Protein S Deficiency
-
Abstract Number: PB0822
A quantitative evaluation of high-molecular forms of von Willebrand factor multimers in children’s with different types of vWD.
-
Abstract Number: PB0933
A randomized clinical trial to evaluate the effect of rosuvastatin with enoxaparin on circulating tissue factor extracellular vesicles following ovarian cancer surgery
-
Abstract Number: VPB1220
A rare case of chronic immune thrombocytopenia with autoantibodies inhibiting platelet aggregation. Effects of romiplostim.
-
Abstract Number: VPB0721
A Rare Case of Factor XII Deficiency Manifesting as bleeding disorder
-
Abstract Number: VPB0315
A rare case of thrombosis with ITP
-
Abstract Number: PB1090
A re-visit of the Pre-Kallikrein (Fletcher trait) assay to optimise for laboratory use
-
Abstract Number: VPB1221
A retrospective analysis of 45 cases of HIV-associated thrombocytopenia in a single center over ten years
-
Abstract Number: PB0685
A Retrospective Database Analysis Study to Evaluate Disease Burden and Treatment Patterns Among Patients With Hemophilia A in China
-
Abstract Number: PB0054
A role for Von Willebrand Factor-ADAMTS13 axis imbalance and abnormal angiogenesis in Long COVID syndrome
-
Abstract Number: PB0806
A screening assay for type 2B von Willebrand factor variants using an ELISA assay with ristocetin and a recombinant wild-type glycoprotein Ib.
-
Abstract Number: PB1063
A sensitive and user-friendly method for quantifying VWF collagen binding (VWF:CB) using a fiber optic – surface plasmon resonance biosensor
-
Abstract Number: PB1107
A specific threshold for ELISA detection of Von Willebrand alloantibodies in patients diagnosed as type 3 von Willebrand disease.
-
Abstract Number: VPB0695
A study of mood state using POMS2 in hemophilia patients
-
Abstract Number: VPB0572
A study of the stability of fibrinogen and FXIII levels and microbial integrity of pooled cyroprecipitate stored at 1-6°C and 20-24°C for up to 120 hours
-
Abstract Number: PB0826
A Systematic Review of Acquired von Willebrand Syndrome Associated With Cardiac Disorders: Epidemiology, Disease Burden, and Management
-
Abstract Number: PB0827
A Systematic Review of Acquired von Willebrand Syndrome Associated With Non-Cardiac Diseases: Epidemiology, Disease Burden, and Management
-
Abstract Number: VPB1378
A systematic review of factors associated with non-adherence to the use of coumarin derivatives or direct oral anticoagulants
-
Abstract Number: PB0298
A Systematic Review of the Current Epidemiology of Immune-Mediated and Congenital Thrombotic Thrombocytopenic Purpura caused by Severe ADAMTS13 Deficiencies
-
Abstract Number: VPB1192
A teenage boy with severe hemophilia A with inhibitors on Emicizumab prophylaxis presenting with hyphema
-
Abstract Number: PB0988
A TEG-guided treatment algorithm for major surgical bleeding
-
Abstract Number: PB1322
A ten-year Australian experience of splanchnic vein thrombosis
-
Abstract Number: OC 48.2
A TEN-YEAR REVIEW OF THE IMPACT OF TRANSITION FROM WARFARIN TO DIRECT ORAL ANTICOAGULANT– HAS VTE TREATMENT BECOME SAFER?
-
Abstract Number: PB1406
A Tertiary Centre Experience of Late Amniocentesis in Obstetric Management of Women with Inherited Bleeding Disorders
-
Abstract Number: OC 36.4
A Tethered Artificial Protease Reveals the Location of Key Regulatory Motifs in Factor V
-
Abstract Number: PB1365
A Tool Integrated in the Electronic Health Record to Guide Proper Decision-Making Regarding Peri-Endoscopic Anticoagulant Use
-
Abstract Number: PB0211
A translational analysis of immune components in peripheral blood from severe hemophilia A patients treated with TAK-754, an AAV8 vector with a codon-optimized B-domain–deleted factor VIII transgene
-
Abstract Number: OC 76.2
A zebrafish model of dysfibrinogenemia caused by hotspot mutations in the human fibrinogen gamma chain
-
Abstract Number: OC 12.2
AAV mediated CRISPR/Cas9 based therapeutic gene-editing with a bypass coagulation factor in a murine model of hemophilia.
-
Abstract Number: PB0927
Abelacimab does not influence the effects of two commonly used antiplatelet agents in vitro
-
Abstract Number: PB0925
Abelacimab has no effect on platelet aggregation induced by TRAP-6 and collagen
-
Abstract Number: PB0548
Abelacimab, a Factor XI/XIa Antibody Inhibits Clotting in Hemodialysis Circuits Ex Vivo
-
Abstract Number: VPB1344
ABO blood group and factor viii level as risk factors for idiopathic venous thromboembolism.
-
Abstract Number: VPB1314
ABO blood group as an additional risk factor for venous thromboembolism
-
Abstract Number: PB0604
Abridging Molecular System Network of COVID-19 and Thrombosis
-
Abstract Number: OC 33.3
Absence of Hypercoagulability after nCoV-19 Vaccination: an observational longitudinal study
-
Abstract Number: OC 58.2
Absence of Protein Tyrosine Phosphatase-1 in Endothelial Cells Promotes Venous Thrombosis by Mechanisms Involving Extracellular Vesicles
-
Abstract Number: PB1083
Accuracy Of The Hyphen Zymutest IgG ELISA Assay For Anti-Platelet Factor 4 Antibody Detection After ChAdOx1 nCov-19 Vaccination In Diagnosing Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)
-
Abstract Number: PB0989
Acquired Factor V Inhibitor In a Patient With Metastatic Cancer
-
Abstract Number: PB0990
Acquired FXI deficiency (aFXIdef) in a HIV + patient with SLE. Alternative evolution to lupus Anticoagulant (LA) during immunosuppressive therapy.
-
Abstract Number: PB0005
Acquired haemophilia presenting in a 14-year-old girl
-
Abstract Number: PO0029
Acquired Hemophilia A: case report
-
Abstract Number: PB0168
Acquired Hemophilia in four north European countries, a survey of 181 patients
-
Abstract Number: PB0241
Acquired Inhibitors: Two Case Studies in Pediatrics
-
Abstract Number: PB0475
Acquired von Willebrand Disease in a Patient Undergoing Extracorporeal Membrane Oxygenation
-
Abstract Number: PB1431
Acquired von Willebrand syndrome in essential thrombocythemia patients referred to special coagulation laboratory of Iranian Blood Transfusion Organization (IBTO)
-
Abstract Number: VPB0003
Acquired von Willebrand syndrome in patients with monoclonal gammopathy: a single centre experience.
-
Abstract Number: PB0474
Acquired von-Willebrand-disease in ECMO or LVAD patients: a comparative cohort study
-
Abstract Number: PO0026
Activated Clotting Time : Setting Target Values of CPB when Changing from Hemochron Resopnse to i-STAT
-
Abstract Number: PB0174
Activated Factor XI as Activator of Thrombin Generation to Increase Assay Sensitivity
-
Abstract Number: PB0018
Activated protein C reduces maladaptive unfolded protein response (UPR) to ameliorate diabetes-accelerated atherosclerosis
-
Abstract Number: OC 44.1
Activation of the Plasma Contact System Triggers the Fat Embolism Syndrome
-
Abstract Number: PO0006
Activity of some coagulative factors and fibrinolysis in patients with arterial hipertension with concomitant diabetes type 2 depending on the carriIage of MTHFR C677T polymorphic genotypes
-
Abstract Number: PB0632
Activity of some protease inhibitors in patients with arterial hypertension of high risk.
-
Abstract Number: VPB0523
Acute arterial limb ischemia after intake of amphetamine derivatives, report of two cases
-
Abstract Number: VPB0148
ADAMTS-13 activity and silent brain infarction in patients with non-ischemic dilated cardiomyopathy
-
Abstract Number: PB0600
ADAMTS13 activity and non-parallel vWF Ristocetin CoFactor activity are associated with severity of COVID-19 infection
-
Abstract Number: PB0091
ADAMTS13 in the diagnosis of the severity of COVID-19 mortality
-
Abstract Number: PB0218
Adaptative methods using one-stage and chromogenic substrate assays for the quantitative measurement of Mim8 in human plasma
-
Abstract Number: PO0044
Adapted Guideline for the Diagnosis and Treatment of Primary Immune Thrombocytopenia in Children in China: Recommendations External Review
-
Abstract Number: PB0777
Adenovirus-based but not mRNA-based vaccines transiently alter platelet count homeostasis in healthy subjects.
-
Abstract Number: PB1131
Adherence and cost effectively of home based prophylaxis over institutionalised based prophylaxis in patients with Hemophilia (PwH) in Upper Assam
-
Abstract Number: PB0447
Adherence and persistence to Direct Oral Anticoagulants (DOACs) in the community following newly diagnosed Venous Thromboembolism (VTE) – a pharmacy-linkage study
-
Abstract Number: VPB0682
Adherence To On Demand Treatment Regimen And Bleeding Outcome (A Multicenter Nigerian Study)
-
Abstract Number: VPB0681
Adherence to prophylaxis and bleeding outcome in haemophilia: A multicentre Nigerian study
-
Abstract Number: PB0960
Adherence to thrombophilia testing guidelines and accuracy of thrombophilia work-up: a single-center cross sectional study
-
Abstract Number: VPB0633
Adipokines and insulin resistance in young individuals with various metabolic phenotypes
-
Abstract Number: PB0972
Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial
-
Abstract Number: PB0294
Adolescent Thrombotic Thrombocytopenic Purpura is a Serious Disorder Requiring Intense Therapies with Significant Morbidity and Relapse
-
Abstract Number: VPB1342
Aetiological profile of inferior veina cava thrombosis
-
Abstract Number: PB0477
Age and sex distribution of the prevalence and incidence of hospitalisations and mortality due to bleeding in England 2014-2019
-
Abstract Number: PB1295
Age related differences in monocyte subsets, cytokine patterns and the production of anti-SARS-CoV-2 antibodies during acute COVID-19 – a prospective observational longitudinal study
-
Abstract Number: OC 10.5
Aging Activates Platelet mTOR to Induce Platelet Hyperreactivity
-
Abstract Number: PB0886
Alcohol intake including wine drinking is associated with decreased platelet reactivity in a large population sample
-
Abstract Number: OC 22.5
Allele-selective inhibition of murine von Willebrand factor in vitro and in vivo
-
Abstract Number: PB0158
AlphaFold and molecular dynamics structure predictions of mutations in serpins: lessons from antithrombin
-
Abstract Number: VPB0611
Alteration of circulating ACE2 regulating microRNAs profiles in patients with COVID-19
-
Abstract Number: VPB0373
Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes: Results from a stepwise hypoglycaemic clamp study
-
Abstract Number: VPB0746
Alterations in Coagulation Profiles and Bleeding Rates in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome on Prophylactic Anti-Bacterials
-
Abstract Number: VPB0130
Alterations in the coagulation profile and mortality due to covid-19 during the first and second wave in peruvians: A retrospective cohort in a national reference center.
-
Abstract Number: PB0592
Altered Fibrin Network Structure and Fibrinolysis in Intensive Care Unit Patients with COVID-19, Not Entirely Explaining the Increased Risk of Thrombosis
-
Abstract Number: PB0303
Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura
-
Abstract Number: PB0324
Alternative anticoagulant treatment in patients with Heparin Induced Thrombocytopenia (HIT). Experience in a high complexity center according to anticoagulants local availability.
-
Abstract Number: PB0641
Alternative cleavage method of LPXTG motif in group A streptococcus by LPXTGase-like protein has a higher selectivity towards aromatic fourth position residues at the sortase A consensus sequence
-
Abstract Number: VPB0251
An Analysis of Factors influencing Survival of Bleeding Patients During First Two Years of Life
-
Abstract Number: PB0225
An engineered factor X variant as a novel by-passing agent for hemophilia
-
Abstract Number: OC 12.4
An Enhanced Hemostatic Factor VIII Variant for Hemophilia A Gene Therapy: Prothrombotic and Immunological Risk Assessment
-
Abstract Number: VPB0253
An Escalating Treatment Strategy for Children with Chronic Immune Thrombocytopenia
-
Abstract Number: OC 09.2
An Extensional Strain-Sensing Mechanosome Drives Rapid Adhesion-Independent Platelet Activation at Supraphysiological Hemodynamic Gradients
-
Abstract Number: PB0707
An Integrated Clinical and Pathological Approach to Rare Bleeding Disorders
-
Abstract Number: OC 69.5
An integrative approach to diagnose heparin-induced thrombocytopenia: development, validation, and implementation of a multivariable prediction model
-
Abstract Number: OC 03.5
An Integrative Biology Approach to Model the Role of the Feedback Activation of FXI by Thrombin in the Tissue Factor Pathway
-
Abstract Number: PB1136
An Observational Study To Evaluate The Impact And Disease Burden In Moderate And Severe Hemophilia From Nursing And Patient Perspective (Study Nurses-Who-Care / ML42270)
-
Abstract Number: VPB0694
Analysis of emicizumab discontinuation in 10 patients with hemophilia A
-
Abstract Number: PB0671
Analysis of F8 Genotypes and Pharmacodynamic and Safety Biomarkers in People with Moderate or Mild Hemophilia A Receiving Emicizumab in the HAVEN 6 Trial
-
Abstract Number: VPB0698
Analysis of Low- and Intermediate-dose Prophylaxis of 30 Adult Patients with Severe Hemophilia A in a Single Center in Nanjing
-
Abstract Number: OC 36.3
Analysis of TFPI-protein S anticoagulant function in vivo.
-
Abstract Number: PB1433
Analysis of uncharacterised Von Willebrand’s Disease causing mutations located in the D4 and C-domains: identification of a novel type 2A variant and gain-of-function VWF
-
Abstract Number: VPB0997
Analytical performance of different laboratory methods for measuring susoctog-alpha
-
Abstract Number: PB0888
Anaphylactic Shock To A Hematological Disorder Patient During Transfusion Of Platelet Aphaeresis Unit Stored In Platelet Additive Solution: A Rare Case Report
-
Abstract Number: OC 65.2
Andexanet alfa is associated with a significant reduction in in-hospital mortality compared to 4F-PCC in a real-world analysis
-
Abstract Number: OC 22.1
Angiopoietin-2 binds to Von Willebrand Factor within Endothelial Cells and after Release from Weibel Palade Bodies and mediates Von Willebrand Factor dependent angiogenesis
-
Abstract Number: VPB0612
Angiostatin and Plasminogen Levels as Risk Factors for Mortality in Hospitalized Covid-19 Patients
-
Abstract Number: PB1123
Annualised Bleeding Rate and Joint Health: Second Interim Analysis of the Real-world HEM-POWR Study Evaluating the Effectiveness of Damoctocog Alfa Pegol in Patients With Haemophilia A
-
Abstract Number: PB0674
Annualized Bleed Rates in Severe Hemophilia A After Switch to Emicizumab Based on CHESS II Data, Including an Oversample of Emicizumab Patients
-
Abstract Number: PB1139
Annualized Bleeding Rates in Severe Hemophilia on Prophylaxis in a Real-World Setting
-
Abstract Number: VPB0316
Anti-ADAMTS13 IgG in congenital TTP patients
-
Abstract Number: VPB0279
Anti-factor Xa-based risk stratification of children receiving therapeutic enoxaparin is associated with increased risk of recurrent/progressive thrombosis and hemorrhage: a retrospective cohort study
-
Abstract Number: PB0164
Anti-inflammatory effect of archaeolipid nanovesicles on human endothelial cells
-
Abstract Number: OC 33.5
Anti-PF4 IgG levels in patients with VITT remain high at 7 months following vaccination and can still activate platelets
-
Abstract Number: PB0596
Anti-SARS-CoV-2 vaccines do not induce a hypercoagulable state in healthy individuals
-
Abstract Number: PB1268
Anti-Thrombotic Effects of the Proteasome Inhibitor Carfilzomib on the Endothelium
-
Abstract Number: PB1073
Anti-Xa and APTT stability in whole blood – a comparison of UFH & LMWH
-
Abstract Number: OC 32.3
Anti-β2-glycoprotein I antibodies cause activated protein C resistance by interfering with Factor V cleavage at Arginine 506
-
Abstract Number: PB0327
Antibody-induced procoagulant platelets cause increased thrombus formation in heparin-induced thrombocytopenia
-
Abstract Number: OC 10.2
Antibody-mediated depletion of human CLEC-2 in a novel humanized mouse model
-
Abstract Number: VPB0944
Anticoagulant associated bleeding risk assessment model for cancer associated thrombosis patients: A systematic review
-
Abstract Number: PB0431
Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis
-
Abstract Number: PB1370
Anticoagulation Control, Outcomes and Associated Factors in Patients Receiving Warfarin in Long-term care in Africa: A Systematic Review
-
Abstract Number: PB1196
Antioxidative capacity of platelets in the pathogenesis of immune thrombocytopenia; Finding the forest for trees
-
Abstract Number: PB0076
Antiphospholipid antibodies in patients with acute ischaemic stroke during the COVID-19 pandemic
-
Abstract Number: PB0414
Antiphospholipid Syndrome-related Venous Thromboembolism: A Nationwide Study
-
Abstract Number: LB 01.5
Antiplatelet effects of inhibiting coagulation factor XI in a non-human primate model of atherosclerosis
-
Abstract Number: PB0914
Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer
-
Abstract Number: OC 67.1
Antithrombin deficiency and altered heparin responsiveness during veno-arterial extracorporeal life support: a prospective study
-
Abstract Number: PB0547
Antithrombin deficiency is associated with more compact plasma fibrin clot structure and impaired susceptibility to fibrinolysis
-
Abstract Number: PB0787
Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and double antiplatelet regimens
-
Abstract Number: PB0042
Antithrombotics and antihistamine use correlated with increased COVID-19 severity. Antithrombotics and antihistamine use correlated with increased COVID-19 severity.
-
Abstract Number: PB0268
Aortic Thrombosis Presenting as Myocardial Infarction in a Child
-
Abstract Number: OC 18.5
APAC Treatment Limits Collar-induced Carotid Atherosclerotic Plaque Development in ApoE-/- Mice
-
Abstract Number: OC 62.3
Apixaban for venous thromboembolism treatment in obese patients with weight >120kg or BMI >40 kg m2
-
Abstract Number: PB0494
Apixaban plasma levels at time of elective surgery: preliminary data from the DALI study
-
Abstract Number: VPB1121
Application of Next-generation sequencing in the study of inherited platelet disorders
-
Abstract Number: VPB1118
Application of prothrombin time clot waveform analysis to assessment of in vitro effects of anticoagulants on normal plasma
-
Abstract Number: PB0080
Are drug-drug interactions clinically relevant?. Use of edoxaban concomitant to ritonavir in COVID-19 hospitalized patients with atrial fibrillation
-
Abstract Number: PB0481
Are levels of direct anticoagulant at the onset of hip fracture surgery associated with post-surgery bleeding?
-
Abstract Number: PB1016
Argatroban Monitoring in Critically Ill Patients and correlation with Thrombin Generation
-
Abstract Number: PB0784
Arginine-containing peptides exhibit antiplatelet effects in experimental type-2 diabetes mellitus and metabolic syndrome
-
Abstract Number: PB0099
Arterial and venous thrombosis induced by vaccination with ChAdOx1 nCov-19 (Astrazeneca) against Coronavirus 19 (COVID19)
-
Abstract Number: OC 13.1
Arterial Thromboembolism Risk Assessment Model in Hospitalized COVID-19 Patients
-
Abstract Number: OC 20.2
Artificial intelligence for the point-of-care ultrasound-based detection of joint effusion in patients with hemophilia
-
Abstract Number: OC 60.5
Artificial Intelligence in the Prediction of Venous Thromboembolism: A Systematic Review and Pooled Analysis
-
Abstract Number: PB0222
Assay of modified factor VIII is modulated by von Willebrand factor. What should we measure ?
-
Abstract Number: PB0226
Assay of the factor VIIIa mimetic, Mim8, using one-stage clotting assay requires a product-specific reference material
-
Abstract Number: PB0874
Assessing Circulation Persistence of Human Platelet Products in a NOD-SCID Mouse Model
-
Abstract Number: PO0072
Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Dabigatran-Anticoagulated Blood
-
Abstract Number: PB0052
Assessing Endothelial Activation and Risk of Bleeding in patients receiving VV-ECMO supportive therapy for COVID-19 using non-standard laboratory assays
-
Abstract Number: VPB0126
Assessing research collaboration networks and social media use among venous thromboembolism researchers during the COVID-19 pandemic
-
Abstract Number: VPB0515
Assessing the cardiovascular risk in patients with Systemic Lupus Erythematosus: QRISK and GAPSS scores head to head
-
Abstract Number: VPB1019
Assessing the reversal efficacy of prothrombin complex concentrate (PCC) and andexanet alfa in rivaroxaban-anticoagulated blood: Ex vivo study
-
Abstract Number: PB0958
Assessment of 3 new functional antithrombin, protein C and protein S assays
-
Abstract Number: VPB0104
Assessment of COVID -19 associated coagulopathy and multiple hemostatic markers in patients of upper Egypt.
-
Abstract Number: OC 71.5
Assessment of DOACs in GEriatrics (ADAGE) study: rivaroxaban and apixaban plasma concentrations and thrombin generation profiles in very elderly patients with non valvular atrial fibrillation
-
Abstract Number: VPB0570
Assessment of Impact of Metabolites of Edoxaban and Dabigatran on Fibrin and Thrombin Generation Assays
-
Abstract Number: PB0991
Assessment of Interference by Emicizumab in the Measurement of Susoctocog Alfa Factor VIII Activity Using a Chromogenic Assay
-
Abstract Number: PB1015
Assessment of Quantra Analyzer on life-threating bleeding under oral anticoagulants agents: a pilot study
-
Abstract Number: VPB0520
Assessment of thrombogenesis activity after endovascular treatment of coronary arteries
-
Abstract Number: PB0485
Assessment of Trauma-Induced Coagulopathy Using a Microfluidic Model of Injury at Venous and Arterial Shear Regimes
-
Abstract Number: VPB1345
Assessment Of Venous Thromboembolism Risk Factors In Hospitalized Patients At The University of Nigeria Teaching Hospital, Enugu Nigeria
-
Abstract Number: VPB1429
Association between a first-trimester retrochorionic hematoma and plasminogen activity level
-
Abstract Number: VPB0204
Association between platelet receptor genotypes and the bleeding tendency of hemophilia patients
-
Abstract Number: VPB0942
Association between RET and BRAF(V600) oncogenic status and risk of venous and pulmonary thromboembolism in patients with papillary thyroid cancer
-
Abstract Number: PB0046
Association between thrombin generation and clinical characteristics in COVID-19 patients
-
Abstract Number: PB0031
Association between thromboembolus composition and first pass recanalisation after thrombectomy in ischemic stroke
-
Abstract Number: PB1233
Association of Genetic Variability in MRVI1Gene in Patients With Arterial Thrombosis and Platelet Hyperaggregability
-
Abstract Number: PB0599
Association of heme/hemopexin/heme-oxygenase 1 pathway with clinical and laboratory markers of severity in Covid-19
-
Abstract Number: OC 23.4
Association of inflammation and coagulation biomarkers with Cerebral Venous Thrombosis Clinical and Imaging characteristics: results from FPCCVT
-
Abstract Number: VPB1217
Association of platelet desialylation and circulating follicular helper T cells in patients with thrombocytopenia
-
Abstract Number: OC 42.5
Association of polygenic risk scores for severe mental illness with risk of venous thromboembolism
-
Abstract Number: PB0037
Association of the FVIII/DD and FvW/DD indices as an indicator of severity and mortality in patients with COVID-19
-
Abstract Number: PB0071
Associations between hemostatic markers and mortality in COVID-19 – compounding effects of amplified coagulation and decreased fibrinolytic activity
-
Abstract Number: PB0512
Associations of Platelete P2y12 Receptor Polymorphism with Macroangiopathies in Patients with High Cardiovascular Risk
-
Abstract Number: VPB1189
ATHN 16: Safety of Coagulation Factor VIIa (recombinant)-jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia A or B with Inhibitors, with or without Prophylactic Treatment
-
Abstract Number: PB0948
ATHNdataset Hereditary Antithrombin Deficiency (HAD) Pilot Project (ATHN 12) Registry from the American Thrombosis and Hemostasis Network (ATHN)
-
Abstract Number: PB0498
Atrial Fibrillation: Trends in Prevalence and Antithrombotic Prescriptions in the Community
-
Abstract Number: VPB0635
Attenuation of Thrombotic Biomarkers in a Hyperlipidaemic Sprague Dawley Rats Model
-
Abstract Number: PB0489
Audit of the use of Fibclot (Fibrinogen concentrate) in patients without congenital afibrinogenaemia
-
Abstract Number: VPB0490
Audit on the use of fresh frozen plasma in a Tertiary Care Hospital
-
Abstract Number: VPB1224
Autoimmune mediated hematological disease associated with COVID-19 disease or vaccination: A multi-centre case series.
-
Abstract Number: PB0151
Automated genotyped matching of platelets to prevent alloimmunisation
-
Abstract Number: OC 16.5
Available Risk Scores Modestly Predict Hemorrhage in Patients with Cancer-Associated Thrombosis (CAT)
-
Abstract Number: PB0395
Avidity-dependent differential signaling by CLEC-2 receptors
ISTH 2022 Congress
July 9-13, 2022. London, England, UK.